{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:47:16Z","timestamp":1762174036225,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41433-025-03985-x","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T06:09:34Z","timestamp":1757398174000},"page":"2912-2917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis"],"prefix":"10.1038","volume":"39","author":[{"given":"Dana","family":"Taghaddos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-0759","authenticated-orcid":false,"given":"Andrew","family":"Mihalache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-5376","authenticated-orcid":false,"given":"Ryan S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-5968","authenticated-orcid":false,"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2886-2011","authenticated-orcid":false,"given":"Clara C.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"3985_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.clindermatol.2023.08.005","volume":"41","author":"A Kudasiewicz-Kardaszewska","year":"2023","unstructured":"Kudasiewicz-Kardaszewska A, Grant-Kels JM, Grzybowski A. Meibomian gland dysfunction and blepharitis: a common and still unsolved ophthalmic problem. Clin Dermatol. 2023;41:491\u2013502.","journal-title":"Clin Dermatol"},{"key":"3985_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0039-6257(96)80064-6","volume":"40","author":"PJ Driver","year":"1996","unstructured":"Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996;40:343\u201367.","journal-title":"Surv Ophthalmol"},{"key":"3985_CR3","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1167\/iovs.10-6997g","volume":"52","author":"G Geerling","year":"2011","unstructured":"Geerling G, Tauber J, Baudouin C, Goto E, Matsumoto Y, O\u2019Brien T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52:2050\u201364.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3985_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jcjo.2021.04.023","volume":"57","author":"J Evans","year":"2022","unstructured":"Evans J, Vo KBH, Schmitt M. Chalazion: racial risk factors for formation, recurrence, and surgical intervention. Can J Ophthalmol. 2022;57:242\u20136.","journal-title":"Can J Ophthalmol"},{"key":"3985_CR5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","volume":"5","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Avogaro A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017;5:680\u20131.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3985_CR6","doi-asserted-by":"publisher","first-page":"e199249","DOI":"10.1001\/jamanetworkopen.2019.9249","volume":"2","author":"GM Dores","year":"2019","unstructured":"Dores GM, Bryant-Genevier M, Perez-Vilar S. Adverse events associated with the use of sipuleucel-T reported to the US Food and Drug Administration\u2019s adverse event reporting system, 2010-2017. JAMA Netw Open. 2019;2:e199249.","journal-title":"JAMA Netw Open"},{"key":"3985_CR7","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","volume":"59","author":"C Zhou","year":"2023","unstructured":"Zhou C, Peng S, Lin A, Jiang A, Peng Y, Gu T, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023;59:101967.","journal-title":"EClinicalMedicine"},{"key":"3985_CR8","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1002\/ajh.23938","volume":"90","author":"J Cortes","year":"2015","unstructured":"Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, et al. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: data from the FDA Adverse Event Reporting System. Am J Hematol. 2015;90:E66\u2013E72.","journal-title":"Am J Hematol"},{"key":"3985_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jamaophthalmol.2021.4778","volume":"140","author":"G McGwin","year":"2022","unstructured":"McGwin G, Maclennan P, Owsley C. Association between pentosan polysulfate sodium and retinal disorders. JAMA Ophthalmol. 2022;140:37\u201342.","journal-title":"JAMA Ophthalmol"},{"key":"3985_CR10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharm. 2011;72:905\u20138.","journal-title":"Br J Clin Pharm"},{"key":"3985_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3985_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30:623\u20135.","journal-title":"Drug Saf"},{"key":"3985_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2165\/00003495-200767010-00006","volume":"67","author":"RM Santaella","year":"2007","unstructured":"Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs. 2007;67:75\u201393.","journal-title":"Drugs"},{"key":"3985_CR14","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1167\/iovs.18-25111","volume":"59","author":"LH Nguyen","year":"2018","unstructured":"Nguyen LH, Makino A, Namkoong P, Yiannakou Y, Narain K. Finasteride-induced clinical ocular toxicity. Invest Ophthalmol Vis Sci. 2018;59:2655.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3985_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.5534\/wjmh.200012","volume":"38","author":"AM Traish","year":"2020","unstructured":"Traish AM. Health risks associated with long-term finasteride and dutasteride use: it's time to sound the alarm. World J Men\u2019s Health. 2020;38:323\u201337.","journal-title":"World J Men\u2019s Health"},{"key":"3985_CR16","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s40123-023-00737-6","volume":"12","author":"A Zakrzewska","year":"2023","unstructured":"Zakrzewska A, Wi\u0105cek MP, S\u0142uczanowska-G\u0142\u0105bowska S, Safranow K, Machali\u0144ska A. The effect of oral isotretinoin therapy on meibomian gland characteristics in patients with acne vulgaris. Ophthalmol Ther. 2023;12:2187\u201397.","journal-title":"Ophthalmol Ther"},{"key":"3985_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0002-9394(01)01024-8","volume":"132","author":"FT Fraunfelder","year":"2001","unstructured":"Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol. 2001;132:299\u2013305.","journal-title":"Am J Ophthalmol"},{"key":"3985_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1167\/iovs.63.3.29","volume":"63","author":"P Zhang","year":"2022","unstructured":"Zhang P, Tian L, Bao J, Li S, Li A, Wen Y, et al. Isotretinoin impairs the secretory function of meibomian gland via the PPAR\u03b3 signaling pathway. Invest Ophthalmol Vis Sci. 2022;63:29.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3985_CR19","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1177\/11206721211018361","volume":"32","author":"C Tanriverdi","year":"2022","unstructured":"Tanriverdi C, Nurozler Tabakci B, Donmez S. Longitudinal assessment of meibomian glands and tear film layer in systemic isotretinoin treatment. Eur J Ophthalmol. 2022;32:885\u201393.","journal-title":"Eur J Ophthalmol"},{"key":"3985_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/sj.pcan.4500939","volume":"10","author":"S Gupta","year":"2007","unstructured":"Gupta S, Silliman CG, Trump DL. Docetaxel-induced meibomian duct inflammation and blockage leading to chalazion formation. Prostate Cancer Prostatic Dis. 2007;10:396\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3985_CR21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamaophthalmol.2015.3963","volume":"134","author":"FW Fraunfelder","year":"2016","unstructured":"Fraunfelder FW, Yang HK. Association between bortezomib therapy and eyelid chalazia. JAMA Ophthalmol. 2016;134:88\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"3985_CR22","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.clml.2016.04.013","volume":"16","author":"MC Veys","year":"2016","unstructured":"Veys MC, Delforge M, Mombaerts I. Treatment with doxycycline for severe bortezomib-associated blepharitis. Clin Lymphoma Myeloma Leuk. 2016;16:e109\u2013e112.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3985_CR23","first-page":"e10062","volume":"12","author":"M Paravathaneni","year":"2020","unstructured":"Paravathaneni M, Thota V, Mulla S, Thirumaran R, Thar YY. A case report on bortezomib-induced bilateral chalazion. Cureus. 2020;12:e10062.","journal-title":"Cureus"},{"key":"3985_CR24","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.18240\/ijo.2022.09.25","volume":"15","author":"CE Gallenga","year":"2022","unstructured":"Gallenga CE, Mura M, Gallenga PE. Suggestions on gut-eye cross-talk: about the chalazion. Int J Ophthalmol. 2022;15:1566.","journal-title":"Int J Ophthalmol"},{"key":"3985_CR25","first-page":"303","volume":"13","author":"F Vingopoulos","year":"2020","unstructured":"Vingopoulos F, Lazzaro DR. Dupilumab-associated blepharoconjunctivits with giant papillae. Int Med Case Rep. J. 2020;13:303\u20135.","journal-title":"Int Med Case Rep. J"},{"key":"3985_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jamadermatol.2018.3427","volume":"154","author":"RM Levine","year":"2018","unstructured":"Levine RM, Tattersall IW, Gaudio PA, King BA. Cicatrizing blepharoconjunctivitis occurring during dupilumab treatment and a proposed algorithm for its management. JAMA Dermatol. 2018;154:1485\u20136.","journal-title":"JAMA Dermatol"},{"key":"3985_CR27","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","volume":"35","author":"MZ Popiela","year":"2021","unstructured":"Popiela MZ, Barbara R, Turnbull AMJ, Corden E, Martinez-Falero BS, O\u2019Driscoll D, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye. 2021;35:3277\u201384.","journal-title":"Eye"},{"key":"3985_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","volume":"84","author":"Y Wang","year":"2021","unstructured":"Wang Y, Jorizzo JL. Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration. J Am Acad Dermatol. 2021;84:1010\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"3985_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/ajd.13924","volume":"63","author":"P Foley","year":"2022","unstructured":"Foley P, Kerdraon YA, Hogden JP, Shumack S, Spelman L, Sebaratnam DF, et al. Dupilumab-associated ocular surface disease: an interdisciplinary decision framework for prescribers in the Australian setting. Australasian J Dermatol. 2022;63:421\u201336.","journal-title":"Australasian J Dermatol"},{"key":"3985_CR30","unstructured":"Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixent\u25bc): risk of ocular adverse reactions and need for prompt management. 2022. Available at: https:\/\/www.gov.uk\/drug-safety-update\/dupilumab-dupixentv-risk-of-ocular-adverse-reactions-and-need-for-prompt-management#dupilumab."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03985-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03985-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:06:25Z","timestamp":1762171585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03985-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":30,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3985"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03985-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"29 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DT: None; AM: None; RSH: None; MMP: Financial support (to institution)\u2014PSI Foundation, Fighting Blindness Canada; CCC: Consultant\u2014Aequus, Abbvie, Admare Bioinnovations, Allergan Inc., Aurion, Bausch & Lomb, Johnson & Johnson Vision, Kala Ophthalmics, Labtician Ophthalmics Inc., Novartis, Santen Inc., Sun Ophthalmics, Thea, Valeo Pharma. Shareholder\u2014Abbott, Pfizer. Financial support (to institution)\u2014Aurion, Corneat, Claris Bio. Lecture fees\u2014Abbvie, Allergan Inc., Johnson & Johnson Vision, Labtician Ophthalmics Inc., Thea.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"An ethics statement was not required for this study type, no human or animal subjects or materials were used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}